CMB.TECH 16.200 € (+1,89 %) AGEAS 75.350 € (+0,80 %) UCB 215.300 € (-0,55 %) HOME INVEST BE. 18.980 € (+0,11 %) ACKERMANS V.HAAREN 272.800 € (-2,29 %) BARCO 7.905 € (-0,32 %) KINEPOLIS GROUP 47.100 € (+1,73 %) SYENSQO 82.150 € (+0,98 %) BEKAERT 39.050 € (+0,90 %) UMICORE 23.700 € (-0,08 %) AB INBEV 68.860 € (+0,85 %) SOFINA 247.800 € (-0,24 %) ARGENX SE 873.800 € (-2,39 %) ONWARD MEDICAL 2.470 € (0,00 %) GBL 73.950 € (+0,14 %) AEDIFICA 67.850 € (-0,73 %) BPOST 1.300 € (-0,61 %) DECEUNINCK 2.445 € (+1,24 %) AZELIS GROUP 12.310 € (+0,33 %) WDP 21.160 € (-0,84 %) RECTICEL 13.280 € (-3,21 %) KBC ANCORA 94.000 € (-0,21 %) D'IETEREN GROUP 178.300 € (+0,96 %) XIOR 26.950 € (-0,55 %) JENSEN-GROUP 74.800 € (+0,27 %) SOLVAY 26.280 € (+2,02 %) KBC 132.150 € (-0,19 %) EXMAR 11.150 € (0,00 %) MONTEA 64.800 € (-1,07 %) VASTNED 28.450 € (-0,18 %) ELIA GROUP 129.200 € (+0,78 %) IBA 16.340 € (-2,97 %) PROXIMUS 6.320 € (-0,47 %) DEME GROUP 174.400 € (-2,13 %) GIMV 43.950 € (-1,12 %) QRF 10.150 € (0,00 %) RETAIL ESTATES 65.600 € (-0,30 %) COLRUYT 38.960 € (-0,05 %) SHURGARD 23.100 € (+0,43 %) ORANGE BELGIUM 22.000 € (0,00 %) TUBIZE-FIN 184.300 € (-1,18 %) CARE PROPERTY INV. 12.020 € (-1,15 %) CENERGY 22.980 € (+1,06 %) EVS 29.850 € (-1,32 %) TESSENDERLO 22.400 € (-3,86 %) BIOTALYS 2.490 € (-0,80 %) BREDERODE 104.000 € (0,00 %) ECONOCOM GROUP 1.485 € (-0,34 %) HYLORIS 4.400 € (-0,45 %) MELEXIS 66.000 € (-0,30 %) VGP 80.800 € (-0,74 %) ASCENCIO 51.500 € (-0,39 %) EKOPAK 4.150 € (+3,75 %) SIPEF 105.000 € (+1,94 %) ONTEX GROUP 2.730 € (-1,97 %) FLUXYS BELGIUM D 22.800 € (+0,88 %) LOTUS BAKERIES 12 800.000 € (+0,16 %) VAN DE VELDE 30.400 € (-0,65 %) AGFA-GEVAERT 0.482 € (+3,77 %) QUESTFOR GR-PRICAF 3.009 € (+1,91 %)
OPMOBILITY 12.680 € (+0,40 %)
CVC CAPITAL 14.640 € (-0,68 %)
FDJ UNITED 22.490 € (+0,36 %)
FERMENTALG 0.457 € (-0,65 %)
SANOFI 77.080 € (-0,22 %)
L'OREAL 390.300 € (+0,46 %)
SIRIUS MEDIA 0.492 € (-3,61 %)
KPN KON 4.142 € (+0,98 %)
AB SCIENCE 0.696 € (-3,73 %)
CARMILA 15.920 € (+0,13 %)
BONDUELLE 8.880 € (+1,02 %)
BIOMERIEUX 74.950 € (-0,40 %)
NOS, SGPS 5.010 € (+0,32 %)
RENAULT 29.700 € (+0,92 %)
THALES 244.100 € (-0,25 %)
AALBERTS NV 44.080 € (+1,19 %)
CTP 14.340 € (-1,38 %)
KERING 255.100 € (+0,35 %)
VALEO 14.380 € (+1,63 %)
ING GROEP N.V. 30.665 € (+0,67 %)
BE SEMICONDUCTOR 196.550 € (-0,48 %)
ASML HOLDING 1 475.000 € (-1,30 %)
North Atlantic En. 85.650 € (+6,53 %)
AHOLD DEL 30.660 € (+0,29 %)
SOCIETE GENERALE 72.620 € (+0,37 %)
VINCI 114.700 € (+0,31 %)
AEGON 8.034 € (+0,10 %)
MAAT PHARMA 2.965 € (-1,98 %)
DERICHEBOURG 9.180 € (+0,33 %)
SAINT GOBAIN 79.580 € (-0,25 %)
VALLOUREC 18.655 € (+5,04 %)
LVMH 457.750 € (-0,09 %)
WAVESTONE 33.950 € (-0,44 %)
FORVIA 9.156 € (+1,31 %)
SCHNEIDER ELECTRIC 299.950 € (-0,60 %)
UNIBAIL-RODAMCO-WE 98.200 € (-0,77 %)
PERNOD RICARD 64.720 € (+2,41 %)
DBV TECHNOLOGIES 2.392 € (+0,76 %)
APERAM 46.940 € (+0,90 %)
AIR LIQUIDE 171.420 € (+0,95 %)
EQUASENS 33.100 € (-0,90 %)
ESSILORLUXOTTICA 161.000 € (-0,22 %)
HAL TRUST 161.600 € (+0,12 %)
TOTALENERGIES 75.980 € (+1,75 %)
DANONE 64.740 € (+0,53 %)
SHELL PLC 39.720 € (+1,47 %)
ENCRES DUBUIT 1.960 € (-2,97 %)
SIGNIFY NV 15.490 € (+0,13 %)
SBM OFFSHORE 35.200 € (+3,23 %)
EBUSCO HOLDING 0.240 € (-0,62 %)
GECINA 69.100 € (-1,29 %)
AUDACIA 5.380 € (-6,60 %)
SECHE ENVIRONNEM. 79.100 € (-2,94 %)
EURONEXT 164.200 € (-0,18 %)
LUMIBIRD 25.200 € (-0,98 %)
BNP PARIBAS ACT.A 103.540 € (+0,96 %)
KALRAY 5.890 € (+3,33 %)
AYVENS 11.350 € (+2,90 %)
SEMCO TECHNOLOGIES 43.100 € (+2,01 %)
SARTORIUS STED BIO 198.000 € (+0,15 %) News Réglementées
|
31/08/2026 09:00
Original-Research: Verbio SE (von NuWays AG): BUYOriginal-Research: Verbio SE - from NuWays AG Classification of NuWays AG to Verbio SE
Renewable fuels entering a new cycle; INITIATE WITH BUY VERBIO is one of Europe's leading integrated biorefineries, converting agricultural feedstocks and residues into biodiesel, bioethanol, biomethane, renewable chemicals and higher-value co-products. Its production network across Germany, the US, Canada and India maximises the value extracted from every tonne of biomass, while providing diversification across products, geographies, feedstocks and regulatory regimes. Following two years of depressed profitability, mainly due to distortions in the German GHG quota market, weak bioethanol economics and the US ramp-up, VERBIO has entered a structural earnings recovery. Preliminary FY25/26 EBITDA reached € 192m (+€ 178m yoy). Excluding a c.€ 20m one-off benefit from GHG quota inventory write-down reversals, underlying EBITDA recovered to c.€ 172m, driven mainly by the normalisation of German GHG quota economics (eNuW: c.2/3 of EBITDA growth), stronger European bioethanol spreads and higher US production. Importantly, the regulatory backdrop is improving as VERBIO completes its largest investment programme. Higher GHG quota prices increase the value of the existing European asset base, while rising utilisation in Nevada, the gradual conversion of South Bend towards integrated ethanol/RNG production and renewable chemicals provide additional operating leverage. The integrated bioethanol/biomethane business remains structurally the most attractive part of the portfolio, combining multiple revenue streams, favourable long-term demand fundamentals and additional upside from the monetisation of CO₂ savings. We believe VERBIO is transitioning from an investment-led to a monetisation-led phase. In addition to the ramp-up of recently completed assets, c.0.66m tonnes of accumulated 2024 GHG quotas (eNuW) represent significant latent value. At our € 400/tCO₂ assumption, these imply c.€ 227m net cash proceeds, which we expect to be monetised across FY27/28e and FY28/29e. The next two months could prove particularly important. FY25/26 results in late September should provide further detail on the earnings recovery, while the Capital Markets Day in early October should offer greater visibility on medium-term earnings potential, capital allocation and the rollout of renewable chemicals. We initiate coverage with BUY and a PT of € 41, based primarily on average normalised FCF across FY27/28e and FY28/29e. Assuming € 400/tCO₂ GHG quota prices, below current spot levels, and no exceptionally strong biofuel margin environment, our forecasts imply an adjusted FCF yield of c.10% in FY27/28e, rising further in FY28/29e, while the market still assigns limited value to regulatory normalisation, recently commissioned assets and renewable chemicals. You can download the research here: verbio-se-2026-08-31-fullnoteinitiation-en-cab0f For additional information visit our website: https://www.nuways-ag.com/research Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse. ++++++++++ The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 2390714 31.08.2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||
© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière